Primary Total: $52,502,661
Total: $42,538,086
Primary Total: $39,077,134
Total: $1,430,012
Primary Total: $1,430,012
*95-H&N-08- Phase II Trial: Taxol (Paclitaxel) 96-Hour Continuous Infusion for Any Stage Anaplastic Carcinoma of the Thyroid, (429650), Bristol Myers, $1.
*Immunotherapy and Gene Therapy of Cancer Program, (433366), Lucille P Markey Charitable Trust, $21,582 (adjustment).
Sister to Sister, (429404), Univ of Illinois, $500.
*New Therapeutic Approaches to Breast Cancer, (433348), Natl Cancer Institute, $139,729.
*Phase 3 Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients with Metastatic
Non-Small Cell Lung Cancer (Protocol B9E-MC-JHEX), (429627), Eli Lilly and Co, $13,230.
*A Phase III, Two-Armed, Multi-Center, Randomized, Controlled Comparison of the Efficacy of Cisplatin Plus Etoposide (VP-16) Versus Cisplatin and Tirapazamine in Subjects with Advanced (Stage IIIB and IV) Lung Tumors, (460025), Sanofi Winthrop Inc, $2.
*A Phase III Open-Label, Multicenter Trial of Actimmune Interferon Gamma-1b (rIFN-Y 1b) in Patients with Metastatic Renal Cell Carcinoma, (427692), Genentech Inc, $6,237 (adjustment).
*Phase II, Open-Label Evaluation of 80 ug/kg/day Intravenous Recombinant Human Macrophage Colony-Stimulating Factor (rhM-CSF) for Four 7-Day Treatment Cycles in Patients with Non-Hodgkin's Lymphoma in First or Second Relapse, (427600), Genetics Institute, $5,688 (adjustment).
*95-LUN-26US: (WR-53) A Phase III Randomized Study of Intensive Cisplatin and Vinblastine + Amifostine in Patients with Stage III-B or Stage IV Non-Small Cell Lung Cancer, (429447), US Bioscience, $2.
Webb Site and Database Development for NAACCR, (429840), North American Assoc Central Cancer Registries, $10,467.
The Costs and Outcomes of Breats Cancer: Merging Claims and Regisrty Data American Cancer Society Institutional Research Grant, (433449), American Cancer Society, $10,000.
*Phase II Study of Chemotherapy with CHOP Followed by ESHAP Chemotherapy in Patients with Intermediate or High Grade Non-Hodgkin's Lymphoma 93-NHL-09, (429482), AMGen, $14,998 (adjustment).
*New Therapeutic Approaches to Breast Cancer, (429581), Natl Cancer Institute, $274,246.
*95-NHL-12ID: (Protocol 102-05) Pivotal Phase II Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients with Relapsed Low-Grade or Follicular B-Cell Lymphoma, (429034), IDEC Pharmaceuticals Co, $7,999 (adjustment).
*Phase II Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Selected Patients with Low-Grade or Follicular B-Cell Lymphoma (IDEC-C2B8 Protocol No. 102-08), (429525), IDEC Pharmaceuticals Co, $2,000.
*Immunotherapy and Gene Therapy of Cancer Program, (428693), Lucille P Markey Charitable Trust, $470,000 (adjustment).
*American Cancer Society Institutional Research Grant, (429411), American Cancer Society, $60,000.
*Anti-Idiotype Vaccine for Breast Cancer, (428687), Natl Cancer Institute, $157,399 (adjustment).
*Southwest Oncology Group, (429737), Natl Cancer Institute, $38,955.
*94-GU-32PD: (Protocol 1003-01) A Double-Blind, Randomized, Phase 3, Multicenter Study of Suramin Versus Placebo in the Treatment of Patients with Metastatic, Hormone-Refractory Prostate Carcinoma (Stage D2), (429033), Warner Lambert Company, $18,500 (adjustment).
*A Randomized, Double-Blind, Placebo Controlled, Multicenter Evaluation of the Efficacy and Safety of SMS 201-995 pa LAR Given with 5-FU in Comparison to Placebo Given with 5-FU in the Treatment of Patients with Stage III or IV Pancreatic, (429674), Sandoz Pharmaceuticals, $7,447.
*94-LUN-19SW (59075-201) Phase II Open Multicenter Study of Intravenously Administered Tirapazamine plus Cisplatin in Subjects with Previously Untreated Extensive Small Cell Lung Cancer, (428518), Sanofi Winthrop Inc, $22,980 (adjustment).
*95-GI-26EL-(Protocol H3E-MC-JMAD) A Phase 2 Trial of LY231514 (Thymidylate Synthase Inhibitor) Administered Intravenously Every 21 Days in Patients with Pancreatic Cancer, (429372), Lily Research Laboratories, $4,500.
*94-MISC-46GI(3004) A Randomized, Double-Blind Comparison of Oral Ondansetron and Intravenous Granisetron in the Prevention of Nausea and Vomiting Associated with Moderately-High Emetogenic Chemotherapy, (428636), Glaxo Inc, $1,500 (adjustment).
*95-GI-25EL-(Protocol H3E-MC-JMAC) A Phase 2 Trial of LY231514 (Thymidylate Synthase Inhibitor) Administered Intravenously Every 21 Days in Patients with Metastatic Colorectal Cancer, (429373), Lily Research Laboratories, $19,125.
A Prospective, Randomized, Multicentre Phase III Clinical Trial Comparing the Effects of PANOREX (17-1A Monoclonal Antibody) Injection Plus 5-Fluorouracil Plus Levamisole Versus 5-Fluorouracil Plus Levamisole in Patients with ..., (429200), Burroughs Wellcome Co., $7,998 (adjustment).
*Phase 2 Trial of Gemcitabine Plus Cisplatin Combination Therapy in Chemonaive Patients with Metastatic Urothelial Cancer (Protocol B9E-MC-JHFY), (460023), Eli Lilly and Co, $2.
*94-MISC-43IS: (IMCL CP-9401) Phase Ib/IIa Study of II-6m in Chemotherapy-Induced Thrombocytopenia in Patients with Advanced Malignancies, (428521), ImClone Systems, $20,251 (adjustment).
*95-MYEL-02ND: (Protocol No. SP-MM-01) A Randomized, Double-Blind, Multicenter Study of Low Dose Gallium Nitrate for Treatment of Bone Involvement Due to Multiple Myeloma, (429446), SoloPak Pharmaceutical Inc, $2,000.
*Recognition of DNA - Carcinogen Adducts by Human MutS Homologs, (433338), American Cancer Society, $15,000.
*For Your Peace of Mind: A Cervical Cancer Video, (429658), KY Department for Health Services, $9,869.
*For Your Peace of Mind: A Cervical Cancer Video, (429589), Virginia Polytechnic Institute and State Univ, $22,000.
*Sister to Sister Breast and Cervical Cancer Outreach Project, (429805), Natl Alliance of Breast Cancer Organizations, $18,663.
*SWOG-9217, Chemoprevention of Prostate Cancer with Finasteride (Proscar) Phase III, (427583), Southwest Oncology Group, $111,835 (adjustment).
*A Randomized, Double-Blind, Multicenter Study of Low- Dose Gallium Nitrate for Treatment of Bone Metastases Due to Breast Cancer, (429626), SoloPak Pharmaceutical Inc, $2,000.
*Antiestrogens Stop Angigenesis; Potential Mechanisms American Cancer Society Instituional Grant, (433446), American Cancer Society, $10,000.
*94-H&N-05AP: (Project #BZ-RM-1; Protocol #02-2.4) Benzydamine HCL in the Prophylactic Treatment of Prostradiation Oral Mucositis, (428690), Angelini Pharmaceuticals Inc Science & Technical, $22,500 (adjustment).
*A Multi-Center, Open Label, Randomized, Controlled, Phase II Trial Evaluating the Efficacy and Safety of BB-10010 in Patients with Breast Cancer or Malignant Lymphoma Receiving High Dose Etoposide and Cyclophosphamide Chemotherapy, (460024), British Biotech Inc, $2.
*NSABP - A Clinical Trial to Determine the Worth of Tamoxifen for Preventing Breast Cancer, (426051), Univ of Pittsburgh, $71,316 (adjustment).
*Conformational Features of Damaged DNA, (433339), American Cancer Society, $15,000.
*Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockade in Clinical B2 (T26NxMo) Prostate Cancer, (426002), TAP Pharmaceuticals Inc, $5,800 (adjustment).
For questions regarding listings, contact Ms. Deborah Davis, director of the Office of Sponsored Projects Administration, 214 Kinkead Hall, 0057, phone 257-8311. (ddavis@pop.uky.edu )
Last Updated: 6/30/03